Company Overview and News

 
New leases on menu as North Sydney emerges as foodie hub

2018-07-27 theage.com.au
North Sydney has turned into a foodie hub with new leases to cater for the increasing number of workers and residents in the area.
CMW

 
New leases on menu as North Sydney emerges as foodie hub

2018-07-27 smh.com.au
North Sydney has turned into a foodie hub with new leases to cater for the increasing number of workers and residents in the area.
CMW

1
What does it take to be a REIT manager?

2018-06-22 theedgemarkets
SINGAPORE (June 22): Earlier in June, John Lim, CEO of ARA Asset Management, and a pioneer of Singapore’ real estate investment trust sector, sat down with The Edge Singapore after just announcing a sterling set of results.
ARSGZ CMW 0778 K2LU 87001 D1R

40
Blackstone Bids $2.38 Billion for Office Tower Fund Investa - Bloomberg

2018-05-28 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BGX CMW DXS BGLF BX IOF BGB

 
Hotel sector seen as red hot for growth

2018-03-16 theage.com.au
The hotel sector is one of the most active for investors with the InterContinental Hotels Group snapping up a controlling stake in the luxe Regents Hotel and Resorts operations.
IHG ICHGF CMW IHG

 
Hotel sector seen as red hot for growth

2018-03-16 smh.com.au
The hotel sector is one of the most active for investors with the InterContinental Hotels Group snapping up a controlling stake in the luxe Regents Hotel and Resorts operations.
IHG ICHGF CMW IHG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:CMW / CROMWELL PROPERTY GROUP on message board site Silicon Investor.

wireless broad band = cmw wireless broad band = cmw wireless broad band = cmw